Related Experiment Video

Updated: Oct 18, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Iván Henríquez1, Mack Roach2, Todd M Morgan3

  • 1Department of Radiation Oncology, Hospital Universitario Sant Joan, 43204 Reus, Spain.

Biomedicines
|September 28, 2021
PubMed

Insights

Metastatic castration-resistant prostate cancer (mCRPC) is complex and progresses rapidly. This review covers current and emerging mCRPC therapies and predictive factors for personalized treatment selection.

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Metastatic castration-resistant prostate cancer (mCRPC) presents diverse molecular profiles and high progression risk.
  • Timely diagnosis and intervention are critical for managing mCRPC patients.
  • Recent advancements have significantly improved mCRPC treatment options, with numerous novel agents under investigation.

Purpose of the Study:

  • To provide a comprehensive overview of current and emerging therapies for mCRPC.
  • To identify clinical and molecular factors that predict patient response to novel treatments.
  • To assist clinicians in navigating the evolving therapeutic landscape of mCRPC.

Main Methods:

  • Narrative review of existing literature on mCRPC treatments.
  • Analysis of clinical trial data and research on therapeutic agents.
  • Synthesis of information on predictive biomarkers for mCRPC.

Main Results:

  • The therapeutic landscape for mCRPC is rapidly evolving with new agents.
  • Identifying predictive biomarkers is essential for optimizing treatment selection.
  • Personalized medicine approaches are increasingly important in mCRPC management.

Conclusions:

  • Clinicians face challenges in staying updated with mCRPC treatment innovations.
  • Understanding patient-specific factors is key to maximizing efficacy of novel therapies.
  • This review offers insights into current and future mCRPC treatment strategies.
Keywords:
androgen deprivation therapymCRPCnovel therapiesprostate cancer

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

7.0K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

13.6K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
741
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.2K